Trial Title	מספר פרוטוקול
NDMM	
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)	BMS IM048-022
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE-POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION	C1071007
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB+ LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA	C1071006
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)	64007957MMY3005
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)	64007957MMY3003
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)	CA089-1043
RRMM	
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)	64407564MMY3009

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy	64407564 - MMY3002
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma	MMY1003
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide	MMY3006
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen Exposed Patients with Relapsed/Refractory Multiple Myeloma	CO43476
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (CAMMA 1).	GO42552
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma	GO43979
M24-108: A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma	M24-108
A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	GO43980
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH Maplirpacept (PF-07901801 (TTI-622)) IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA	C1071020

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells	CyR4MM-041
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM).	CC-220-MM-002
A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma	XPORT-MM-028
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 [=mezigdomide], BORTEZOMIB AND DEXAMETHASONE (480VD) VERSUS POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (PVD) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	CA057-001
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2	CA057-008
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma	M21-406
Phase 1 study of CART BCMA in multiple myeloma patients presenting BCMA	MOH_2020-12-22_009584
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma	SHEBA-21-8048-HM-CTIL
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)	R5458-ONC-2245
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)	BGB-11417-105
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab	64407564MMY3009
A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with	M22-574

A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects with Relapsed or Refractory Multiple Myeloma	M23-001
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM)	ACT16482
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma (MajesTEC-10)	64007957MMY1008

זרועות הטיפול	קו טיפול	תנאי הכללה	
		תרופות קודמות ותנאים - חובה	תרופות קודמות- אסורות ותנאי אי-הכללה
Iberdomide Vs Lenalidomide	1	After ASCT	
Elranatamab (PF-06863135) Vs Revlimid	1	MRD positive after ASCT	Maintenance treatment Anti-BCMA treatment
Part 1: Elranatamab+Dara+Len Part 2: Elranatamab+Dara+Len VS DRd	1 Part 1 RRMM: 2,	Part 1: RRMM or NDMM ASCT ineligible Part 2: NDMM ASCT ineligible	PART1 only: BCMA-directed therapy or anti-CD38 therapy ≤ 6 months, or anti-CD38 Refractory ASCT ≤3 months
Arm A: Tec-DR Arm B: Tal-DR Arm C: DRd	1	NDMM	
Arm A: Tec-Len Arm B: Len Arm C: Tec	1	Triplet or quadruplet FL regimen ≥PR on FL After ASCT	Maintenance Anti-BCMA PD before screening
Arm A: ide-cel + LEN maintenance **Arm B: LEN maintenance alone**	1	4-6 cycles of induction (including IMiD + PI) ASCT (80-120 days) PR or VGPR post ASCT	**non-secretory MM** **any therapy post ASCT**
Arm A: Tal-Pd Arm B: Tal-Tec Arm C: Elo+Pd or PVd (control)	2,3,4,5	Lenalidomide - Min 2 cycles Anti-CD38 - Min 2 cycles	GPRCD5-directed therapy Pomalidomide Teclistamab ARM C: Elotuzumab

A: Tal-DP B: DPd C: Tal-D		R/R PI, Lenalidomide 2nd line - Len refracory >= 3rd line - Len exposed	Refractory to anti-CD38 MAB Pomalidomide CART or BITE < 3 Months ASCT < 12 weeks
Tal+Tec Dara+Tal+Tec	3, 4, 5, 6	IMiD Anti-CD38 PI	Dara cohort: anti BCMA, GPRC5D
A - Teclistamab B - PVd/Kd	2, 3, 4	PD or SD on previous line. =>PR on Bortezomib Exposed to anti-CD38 and Len.	Prior BCMA-directed therapy Poma (for PVd) Kypro (for Kd) Dexa intolerence
Cevostamab	Any	PI IMiD Anti-CD38 Anti-BCMA	Bi-specific AB
B Cevostamab זרוע Pomalidomide+ Dexamethason+	>=2	PI IMiD	Anti-FcRH5
Cevostamab+Elranatamab +Tocilizumab	>=2	PI, IMiD Anti-CD38 or ≥3 lines without anti-CD38	Cevostamab, or another agent targeting FcRH5 Elranatamab Allogeneic SCT
ABBV-383	>=3	PI, IMiD, Anti-CD38, ARM B: Prior BCMA-directed therapy	
Arm A: XmAb24306 + cevostamab Arm B: Single-agent cevostamab	>=4	PI, IMiD, Anti-CD38	CD3/BCMA (optional)
Part 1: Elranatamab+Kd Part 2: Elranatamab+Maplirpacept	Part 1: 2,3,4 Part 2: >=4	Carfilzomib allowed under conditions Part 2: Triple refractory	

Cyclo+Kd	2, 3	Bortezomib - Exp. Lenalidomide - Exp. Daratumumab - Exp. Carfilzomib - <MR after 2 cycles or refractory	Cyclosporine Carfilzomib
A: Iberd-Dara-Dexa B: Bort-Dara-Dexa	2, 3	RRMM ≥MR on Bortezomib	Stage 1 - CD38 therapy Refractory to Velcade
Sd - 40 BIW Sd - 80 BIW Sd - 100 QW	5, 6	2 PIs 2 IMiDs anti-CD38	Selinexor
MVd PVd	2, 3, 4	Lenalidomide >=MR to at least 1 prior line	RR on PI If received Bortezomib - less than MR, or toxicity
MezigKd VS Kd	>=2	Lenalidomide Anti-CD38 >=MR to at least 1 prior line	
ABBV-453	Any	t(11:14) and BCL2-high gene expression. RR to all established MM therapies.	
CART anti BCMA	>=3	triple exposed, prior 3 LNs;	
CART anti BCMA	>=3	10% plasma cells in bone marrow	
Arm 1: Linvoseltamab Arm 2: Elotuzumab + Pd	2-5	Lenalidomide PI Anti-CD38	Elotuzumab Pomalidomide Anti-BCMA (not including ADC).
Part 2: BGB-11417/ BGB-11417 + Dexa/ BGB-11417 + Dexa + Carfilzomib/ Carfilzomib + Dexa	Part 1: >3 Part 2: >1	RRMM t(11;14)	BCL2 (e.g. - Venetoclax) Carfilzomib refractory or <6Mo
Arm A: Tal-Pd Arm B: Tal-Tec	2,3,4,5	Lenalidomide - Min 2 cycles	GPRCD5-directed therapy
Arm 1: ABBV-383 Arm 2: SAT (Kd/ EloPd/ SVd)	>=3	RRMM, secretory PI, IMiD, Anti-CD38	anti-BCMA Arm 2 only: Carfilzomib, Elotuzumab, Selinexor ≥ PR and > 6 months since last PI

Part 1: Cycle 1 SC, Cycle 2+ IV Cohort 1: 80 mg SC (first 6 patients worldwide) Cohort 2: 96 mg SC Part 2: only SC	>=2	RRMM PI or IMiD or anti-CD38	BCMAxCD3 bispecific antibody.
A) Substudy 01: Isatuximab + Poma + Dexa (control) B) Substudy 04: Isatuximab + Pegenzileukin C) Substudy 05: Isatuximab + Belumosudil + Dexa	≥3	A) RRMM B&C) RRMM anti-CD38 anti-BCMA D)RRMM	afer exposure; PD or toxicity on Isa/Pom/Dex regimen D) allo-HSCT anti-CD47 anti SIRPα agent
Arm A: Pre-change Teclistamab Arm B: Post-change Teclistamab	2-4	RRMMPIIMiDAnti-CD38	Bi-Specific ABAnti-BCMA

PI	IMiD	DARA	BCMA	Anti-CD38	Velcade	LEN	POM
			N				
E	E						
				E		By prior lines: 1 - R 2 - E	

E/R		E/N				2nd line - R 3rd line - E	N
R	R	R					
				E		E	
R	R	R	E/R				
E/R	E/R						
E	E			E			
E	E			E			

		E			E	E	
		Stage 1: N Stage 2: E			E		
E/R	E/R			R			
E/N						E/R	N
E/R	E/R	E/R	E/R		E/R	E/R	E/R
R	R	R					
R	R	R					
E				E		E	
E	E			E			
				E		By prior lines:	
E	E			E			

E	E			E			

NTC/MOH	יזם		מרכזים
	ISS/Sponsor	Sponsor name	
NCT05827016	Sponsor	Celgene	שיבא רמבם שערי צדק הדסה אסותא אשדוד
NCT05317416	Sponsor	Pfizer	הדסה, שיבא, איכילוב, רמבם , בילינסון, סורוקה, שערי צדק
NCT05623020	Sponsor	Pfizer	הדסה שיבא
NCT05552222	Sponsor	Janssen	איכילוב שערי צדק שיבא רמבם הדסה - החל מספטמבר 24
NCT05243797	Sponsor	European Myeloma Network	רמבם איכילוב
NCT06045806	Sponsor	**BMS**	
NCT06208150	Sponsor	Janssen	איכילובשיבא

NCT05455320	Sponsor	Janssen	~~שיבא~~ ~~רמבם~~ ~~שערי צדק~~ ~~בילינסון~~ ~~בני ציון~~ ~~נהריה~~ ~~העמק~~
NCT04586426	Sponsor	Janssen	שיבא, הדסה
NCT05572515	Sponsor	Janssen	איכילוב, בילינסון שיבא איכילוב בני ציון
NCT05535244	Sponsor	Roche	איכילוב שיבא הדסה
NCT04910568	Sponsor	Genentec	איכילוב רמבם
NCT05927571	Sponsor	Genentech	איכילוב רמבם שיבא
NCT05650632	Sponsor	ABBVIE	איכילוב בילינסון הדסה שיבא
NCT05646836	Sponsor	Genentec	בילינסון איכילוב
NCT05675449	Sponsor	Pfizer	הדסה רמבם שיבא איכילוב

NCT04813653	ISS	איכילוב	איכילוב
NCT04975997	Sponsor	Celgene	איכילוב רמבם הדסה שיבא העמק
NCT04414475	Sponsor	Karyopharm Therapeutics, Inc.	הדסה, שיבא, איכילוב, אסותא אשדוד, רמבם , בני ציון, העמק, שערי צדק, מאיר, בלינסון
NCT05519085	Sponsor	Celgene	איכילוב, הדסה, רמבם, שיבא, בילינסון, מאיר
NCT05552976	Sponsor	Celgene	הדסה
NCT03215030	Sponsor	AbbVie	שיבא הדסה
NCT04720313	ISS	הדסה	הדסה
NCT05243212	ISS	שיבא	איכילוב שיבא
R5458-ONC-2245	Sponsor	Regeneron	איכילוב הדסה שערי צדק שיבא רמבם
NCT04973605	Sponsor	BeiGene	איכילוב
NCT06208150	Sponsor	Janssen	איכילובשיבא
NCT06158841	Sponsor	AbbVie	איכילובשערי צדקשיבא

NCT06223516	Sponsor	AbbVie	איכילובהדסהשיבא
NCT04643002	Sponsor	Sanofi	איכילובהדסהשיבא
NCT06425991	Sponsor	Janssen	איכילוב

מספר פרוטוקול	Trial Title	זרועות הטיפול

CAEL 101-301	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis	D-Cy-Bor-d-Placebo VS D-Cy-Bor-d CAEL-101
CAEL 101-302	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Dara- CyBorD-Placebo VS Dara- CyBorD CAEL-101
NEOD001-301	A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)	standard of care + birtamimab or placebo

P.I	מתאם/ת	פרוטוקול המחקר	תנאי הכללה		קוי טיפול
			תרופות קודמות- אסורות	תרופות קודמות ותנאים - חובה	
יעל כהן	תמר	קישור לפרוטוקול			1
יעל כהן	תמר	קישור לפרוטוקול			1

Status	Medical Center/ Trial	ISS/Sponsor	Sponsor name
Recruiting	שיבא רמבם בלינסון איכילוב	Sponsor	Alexion Pharmaceuticals, Inc
Recruiting	שיבא רמבם בלינסון איכילוב	Sponsor	Alexion Pharmaceuticals, Inc
	הדסהרמבם בני ציון בילינסון		

הערות (שינויים)

https://clinicaltrials.gov/ct2/show/NCT04512235\

https://clinicaltrials.gov/ct2/show/NCT04512235

https://clinicaltrials.gov/ct2/show/NCT04973137

מספר פרוטוקול	Trial Title	זרועות הטיפול
68284528 -MMY3002	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)	Arm A - DPd/PVd Arm B - CarT
M13-494	A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	Venetoclax+dex vs Pom+Dex
MMY2003	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)	Car-T
	A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)	
MMY1001	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	~~A - 400 µg/kg~~ B - 400 µg/kg ~~C - 800 µg/kg~~
EFC15992(ITHACA)	Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (ITHACA)	ILD - Isa+Rd LD - Rd
DREAMM 7	Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)	
CC-220-MM-002	Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM).	
GO42552	מחקר פאזה ib בתווית-פתוחה, רב-מרכזי, להערכת הבטיחות, הפרמקוקינטיקה והפעילות של סבוסטאמאב בחולי מיאלומה נפוצה נשנית או עמידה לטיפול (CAMMA 1)	Cevostamab
CPHE885B12201	**A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma**	PHE885
DREAMM8	Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)	B-Pd VPd

CC-220-MM-001	**A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CC-220 AS MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH MULTIPLE MYELOMA**	CC-220 as monotherapy, with DEX, Dara, Bortezomib or Carfilzomib
CWVT078A12101	A Study of WVT078 in Patients With Multiple Myeloma (MM)	A: WVT078 B: WVT078 + WHG626
CVOB560A12101	VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)	A: R/R NHL and R/R MM B: R/R AML.
MMY3004	**A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)**	A: VRD->RD B: VRD->CarT
IPoD790	**Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)**	IPoD
CPHE885B12201	**Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma**	PHE885
TAK-573-1501	**A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma**	Modakafusp alfa 120mg Modakafusp alfa 240mg
ZN-d5-003	A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	ZN-d5

קוי טיפול	תנאי הכללה		פרוטוקול המחקר	מתאם/ת
	תרופות קודמות ותנאים - חובה	תרופות קודמות- אסורות ותנאי אי-הכללה		
קיבלו בעבר 1-3 קווים	PI, IMiD. Recractory to Lenalidomide.	CarT, BCMA targeted therapy	קישור לפרוטוקול	עדן
קיבלו לפחות 2 קווים בעבר	PI, R/R to Lenalidomide, t(11:14)	Venetoclax or another BCL-2 inhibitor. Pomalidomide. Autologous SCT within 12 weeks	קישור לפרוטוקול	שני / תמר / מאיה
~~A - PD after 1-3 lines including PI and IMiD, no BCMA~~ ~~B - Early relapse after 1 line, no BCMA~~ ~~C - R/R after PI, IMiD, anti-CD38 and BCMA~~ ~~D - Line 1, no CR after induction and ASCT - 4-8 cycles~~ ~~E - hr-NDMM, not planned for ASCT~~ **F - Standard risk (ISS 1&2) NDMM, >=VGPR after 4-8 cycles of KRd or D-KRd.**			קישור לפרוטוקול	עדן
>=3 prior lines	~~**A&C:** 1 PI, 1 IMiD, 1 anti-CD38~~ **B**: 1 PI, 1 IMiD, 1 anti-CD38 MAB and CarT or BiTE	~~A: CarT or BiTE~~ B: None ~~C: CarT or BiTE~~	קישור לפרוטוקול	שני / תמר / מאיה
<5 years of HR-SMM diagnosis			קישור לפרוטוקול	שני
				שני / תמר / מאיה
4, 5, 6	PI IMiD			
>=3	R/R IMiD, PI, anti-CD38	CART- BCMA Anti BCMA ASCT < 3 months	R	R
2	Lenalidomide Dara ASCT>100 days or not eligible.	Bortezomib - Intolerant or refractory Pomalidomide BCMA [ISRAEL: only 2nd line post DARA]		

Part 1 (Dose escalation) - RRMM Part 2 - Any	Part 1 - 1-3 Prior lines, depending on cohort. Exposed to Len, PI (and Pom in 1 cohort).	Nonsecretory MM PCL or amyloidosis	E/R	
>=2	PI IMiD Anti-CD38	Not eligible for treatment with other regimens known to provide clinical benefit		
>=3	R/R after PI, IMiD, anti-DC38	ASCT < 3 months Not eligible for treatment with other regimens known to provide clinical benefit		
1	ASCT not planned	CarT, BCMA targeted therapy Any prior therapy for MM or SMM (1 VRd cycle allowed)		
2, 3	Bortezomib Lenalidomide Daratumumab	Ixazomib Pomalidomide		
>=3	R/R IMiD, PI, anti-CD38	CART- BCMA Anti BCMA ASCT < 3 months	R	R
>=3	Refractory to IMid, pi & anti-CD38 AB. >=MR to at least 1 prior line.	IgM myeloma ASCT < 60 days	R	R
2, 3, 4			קישור לפרוטוקול	שני

P.I	Status	Medical Center/ Trial	יזם	
	Status		**ISS/Sponsor**	**Sponsor name**
עירית אביבי	Active - not recruiting	NCT04181827	Sponsor	Janssen
עירית אביבי	Not Recruiting	NCT03539744	Sponsor	Abbvie
יעל כהן	Not Recruiting	NCT04133636	Sponsor	Janssen
	Completed	NCT03151811		
יעל כהן	Not Recruiting	NCT04634552	Sponsor	Janssen
עירית אביבי	Not Recruiting	NCT04270409	Sponsor	sanofi-aventis
	Not Recruiting	NCT04246047		
	not yet Recruiting pending sponsor post initiation	NCT04975997		
	FDA HOLD			
R				

		E/R - Part 2 in Cohorts C, D, and I		E/R
E/R			E/R	E/R
R				
R				
יעל כהן	Recruiting	הדסה שיבא איכילוב רמבם	Sponsor	K-Group Alpha

Is the status updated?	הערות (שינויים)	
Yes		
Yes	Not recruiting	**TBD - Siva**
Yes	קוהורט F בלבד, חולים עם אינדוקציה של KRD או DARA-KRD	
Yes	אפשר למחוק!	
Yes	only B open(post CART)	
Yes	closed for reruitment	
Yes		
Yes	לברור	
	קישור לפרוטוקול	
	קישור לפרוטוקול	שני / תמר / מאיה

		E/R (cohort D)
מאיה	קישור לפרוטוקול	
שני / תמר / מאיה	קישור לפרוטוקול	
שרון / עדן	קישור לפרוטוקול	
שני	קישור לפרוטוקול	N
	קישור לפרוטוקול	
	קישור לפרוטוקול	
	https://clinicaltrials.gov/ct2/show/NCT05199337	

n will ask Abbvie

איכילוב שיבא	Novartis	Sponsor	עירית אביבי	
~~איכילוב~~, סורוקה, אסותא אשדוד, רמבם, שערי צדק, מאיר, בלינסון	GSK	Sponsor	NCT04484623	עירית אביבי

	NCT0277303	Sponsor	Celgen	~~איכילוב שיבא~~
יעל כהן	NCT04123418	Sponsor	Novartis	~~איכילוב~~
עירית אביבי	NCT04702425	Sponsor	Novartis	~~איכילוב~~
יעל כהן	NCT04923893	Sponsor	Janssen	הדסה, שיבא, איכילוב
יעל כהן	NCT04790474	ISS		הדסה, שיבא, איכילוב, רמבם, העמק, שערי צדק, בלינסון
עירית אביבי	CT0431832	Sponsor	Novartis	איכילוב ~~שיבא~~
יעל כהן	CT0321503	Sponsor	Takeda	שיבא, הדסה, איכילוב